Killing the golden goose of US drug innovation (Part I): Follow the money

In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

12 September 2025 In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.

Biotechnology

An update on patenting in Ukraine, Russia and Eurasia

2 September 2025 Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.

More features

Less is more: patent lawyers flip the script after Amgen

‘Doing more with less’: In-house counsel on budgets and strategy

End of the ‘Death Squad’? Squires puts PTAB on trial

Data and delivery: Inside AI's inventorship dilemma

Weil continues expansion with top trade secrets litigator

Top pharma, biotech, and medtech experts gather at LSPN Fall

Mitsubishi Tanabe doubles down on Radicava protection

‘All it takes is a post on Truth Social’: Is this patent reform's moment?

Killing the golden goose of US drug innovation (Part I): Follow the money

More on this story

Editor's picks

Editor's picks

More features